Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 4,196 INR
Change Today -50.95 / -1.20%
Volume 278.8K
DRRD On Other Exchanges
New York
As of 7:05 AM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/14/15 - 4,338
52 Week Low
10/17/14 - 2,867
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as anti-infective, metabolic disorders, and pain and inflammation. It also provides differentiated formulations for unmet medical needs; and a portfolio of in-licensed patented dermatology products As of March 31, 2015, this segment had 18 active products in proprietary products development pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

20,373 Employees
Last Reported Date: 06/17/15
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Managin...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2015.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy's Laboratories Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

Dr. Reddy's Laboratories announced that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM (esomeprazole magnesium) Delayed-Release Capsules in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA). The NEXIUM (esomeprazole magnesium) Delayed-Release Capsules brand and generic had U.S. sales of approximately $5.2 Billion MAT for the most recent twelve months ending in July 2015 according to IMS Health. Dr. Reddy’s ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg are available in bottle count size of 30.

Dr. Reddy's Laboratories Ltd. Approves Adoption of New Articles of Association

Dr. Reddy's Laboratories Ltd. announced that the shareholders of the company approved the adoption of new articles of association of the company through the postal ballot.

BioMarin Pharmaceutical Inc. Enters into a Settlement Agreement with Dr. Reddy's Laboratories, Inc

BioMarin Pharmaceutical Inc. announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories Inc. that resolves patent litigation in the United States (U.S.) related to BioMarin's Kuvan (sapropterin dihydrochloride) 100mg oral tablets. Under the terms of the settlement, BioMarin will grant Dr. Reddy's a non-exclusive license to its patents related to Kuvan to allow Dr. Reddy to market a generic version of sapropterin dihydrochloride 100mg tablets in the U.S. for the indications approved for Kuvan beginning at a confidential date in the future, but which is more than five years from September 18, 2015, or earlier under certain circumstances. Additional details of the agreement remain confidential. BioMarin continues to vigorously enforce its intellectual property related to Kuvan. This includes continuing its suit against Par Pharmaceutical Inc., which is not affected by this settlement. As required by law, BioMarin and Dr. Reddy will submit the Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 4,195.55 INR -50.95

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 744.60 INR -10.55
Croda International PLC 2,721 GBp -56.00
Endo International PLC $63.14 USD -0.96
Sigma-Aldrich Corp $139.57 USD +0.10
Symrise AG €55.62 EUR +0.171
View Industry Companies

Industry Analysis


Industry Average

Valuation DRRD Industry Range
Price/Earnings 30.4x
Price/Sales 4.6x
Price/Book 5.9x
Price/Cash Flow 30.4x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at